RATIONALE: Few noninvasive biomarkers for pulmonary inflammation are currently available that can assess the lung-specific response to antiinflammatory treatments. Positron emission tomography with [(18)F]fluorodeoxyglucose (FDG-PET) is a promising new method that can be used to quantify pulmonary neutrophilic inflammation. OBJECTIVES: To evaluate the ability of FDG-PET to measure the pulmonary antiinflammatory effects of hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) and recombinant human activated protein C (rhAPC) in a human model of experimentally-induced lung inflammation. METHODS:Eighteen healthy volunteers were randomized to receive placebo, lovastatin, orrhAPC before intrabronchial segmental endotoxin challenge. FDG-PET imaging was performed before and after endotoxin instillation. The rate of [(18)F]FDG uptake was calculated as the influx constant K(i) by Patlak graphical analysis. Bronchoalveolar lavage (BAL) was performed to determine leukocyte concentrations for correlation with the PET imaging results. MEASUREMENTS AND MAIN RESULTS: There was a statistically significant decrease in K(i) in the lovastatin-treated group that was not seen in the placebo-treated group, suggesting attenuation of inflammation by lovastatin treatment despite a small decrease in BAL total leukocyte and neutrophil counts that was not statistically significant. No significant decrease in K(i) was observed in the rhAPC-treated group, correlating with a lack of change in BAL parameters and indicating no significant antiinflammatory effect with rhAPC. CONCLUSIONS: FDG-PET imaging is a sensitive method for quantifying the lung-specific response to antiinflammatory therapies and may serve as an attractive platform for assessing the efficacy of novel antiinflammatory therapies at early phases in the drug development process. Clinical trial registered with www.clinicaltrials.gov (NCT00741013).
RCT Entities:
RATIONALE: Few noninvasive biomarkers for pulmonary inflammation are currently available that can assess the lung-specific response to antiinflammatory treatments. Positron emission tomography with [(18)F]fluorodeoxyglucose (FDG-PET) is a promising new method that can be used to quantify pulmonary neutrophilic inflammation. OBJECTIVES: To evaluate the ability of FDG-PET to measure the pulmonary antiinflammatory effects of hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) and recombinant human activated protein C (rhAPC) in a human model of experimentally-induced lung inflammation. METHODS: Eighteen healthy volunteers were randomized to receive placebo, lovastatin, or rhAPC before intrabronchial segmental endotoxin challenge. FDG-PET imaging was performed before and after endotoxin instillation. The rate of [(18)F]FDG uptake was calculated as the influx constant K(i) by Patlak graphical analysis. Bronchoalveolar lavage (BAL) was performed to determine leukocyte concentrations for correlation with the PET imaging results. MEASUREMENTS AND MAIN RESULTS: There was a statistically significant decrease in K(i) in the lovastatin-treated group that was not seen in the placebo-treated group, suggesting attenuation of inflammation by lovastatin treatment despite a small decrease in BAL total leukocyte and neutrophil counts that was not statistically significant. No significant decrease in K(i) was observed in the rhAPC-treated group, correlating with a lack of change in BAL parameters and indicating no significant antiinflammatory effect with rhAPC. CONCLUSIONS:FDG-PET imaging is a sensitive method for quantifying the lung-specific response to antiinflammatory therapies and may serve as an attractive platform for assessing the efficacy of novel antiinflammatory therapies at early phases in the drug development process. Clinical trial registered with www.clinicaltrials.gov (NCT00741013).
Authors: N P O'Grady; H L Preas; J Pugin; C Fiuza; M Tropea; D Reda; S M Banks; A F Suffredini Journal: Am J Respir Crit Care Med Date: 2001-06 Impact factor: 21.405
Authors: Helen Ilumets; Paula H Rytilä; Anssi R Sovijärvi; Taina Tervahartiala; Marjukka Myllärniemi; Timo A Sorsa; Vuokko L Kinnula Journal: Scand J Clin Lab Invest Date: 2008 Impact factor: 1.713
Authors: Vanessa Zambelli; Giuseppe Di Grigoli; Margherita Scanziani; Silvia Valtorta; Maria Amigoni; Sara Belloli; Cristina Messa; Antonio Pesenti; Ferruccio Fazio; Giacomo Bellani; Rosa Maria Moresco Journal: Intensive Care Med Date: 2012-01-26 Impact factor: 17.440
Authors: Antonio Pesenti; Guido Musch; Daniel Lichtenstein; Francesco Mojoli; Marcelo B P Amato; Gilda Cinnella; Luciano Gattinoni; Michael Quintel Journal: Intensive Care Med Date: 2016-03-31 Impact factor: 17.440
Authors: Guido Musch; Tilo Winkler; R Scott Harris; Marcos F Vidal Melo; Tyler J Wellman; Nicolas de Prost; Richard L Kradin; Jose G Venegas Journal: Anesthesiology Date: 2014-03 Impact factor: 7.892
Authors: Howard J Huang; Warren Isakow; Derek E Byers; Jacquelyn T Engle; Elizabeth A Griffin; Debra Kemp; Steven L Brody; Robert J Gropler; J Philip Miller; Wenhua Chu; Dong Zhou; Richard A Pierce; Mario Castro; Robert H Mach; Delphine L Chen Journal: J Nucl Med Date: 2014-12-18 Impact factor: 10.057
Authors: Albert Wu; Huaiyu Zheng; Jennifer Kraenzle; Ashley Biller; Carol D Vanover; Mary Proctor; Leslie Sherwood; Marlene Steffen; Chin Ng; Daniel J Mollura; Colleen B Jonsson Journal: ILAR J Date: 2012
Authors: Yuefei Shen; Ritu Shrestha; Aida Ibricevic; Sean P Gunsten; Michael J Welch; Karen L Wooley; Steven L Brody; John-Stephen A Taylor; Yongjian Liu Journal: Interface Focus Date: 2013-06-06 Impact factor: 3.906